Karyopharm Therapeutics Inc., a Natick, Massachusetts-based clinical-stage biopharmaceutical company, raised $48.2m in Series B financing.
The round was led by a private investor with participation from Delphi Ventures. In conjunction with this investment, Delphi’s Deepa Pakianathan, PhD, will join Karyopharm’s Board of Directors.
The company intends to use the funds to advance its pipeline of novel Selective Inhibitors of Nuclear Export (SINE) drug candidates for the treatment of advanced hematologic and solid tumors.
Founded by Drs. Sharon Shacham and Michael Kauffman in late 2008 Led by Michael Kauffman, M.D., Ph.D, Chief Executive Officer, Karyopharm is currently testing KPT-330 in two separate Phase 1 trials. The Company is also testing the related SINE KPT-335 in a pivotal study as an oral treatment for dogs with Non-Hodgkin’s Lymphoma and SINEs in autoimmune, viral and dermatologic disorders.
FinSMEs
21/05/2013